Concise Review: Tissue Engineering of Urinary Bladder; We Still Have a Long Way to Go?

Jan Adamowicz, Marta Pokrywczynska, Shane Vontelin Van Breda, Tomasz Kloskowski, Tomasz Drewa

Key Words. Stem cells • Urinary bladder • Regeneration • Translational medicine • Urology

ABSTRACT

Regenerative medicine is a new branch of medicine based on tissue engineering technology. This rapidly developing field of science offers revolutionary treatment strategy aimed at urinary bladder regeneration. Despite many promising announcements of experimental urinary bladder reconstruction, there has been a lack in commercialization of therapies based on current investigations. This is due to numerous obstacles that are slowly being identified and precisely overcome. The goal of this review is to present the current status of research on urinary bladder regeneration and highlight further challenges that need to be gradually addressed. We put an emphasis on expectations of urologists that are awaiting tissue engineering based solutions in clinical practice. This review also presents a detailed characteristic of obstacles on the road to successful urinary bladder regeneration from urological clinician perspective. A defined interdisciplinary approach might help to accelerate planning transitional research tissue engineering focused on urinary tracts.

SIGNIFICANCE STATEMENT

The goal of this review is to present the current status of research on urinary bladder regeneration and highlight further challenges that need to be gradually addressed. We put an emphasis on expectations of urologists that are awaiting tissue engineering based solutions in clinical practice. This review presents a detailed characteristic of obstacles on the road to successful urinary bladder regeneration from a urological clinician perspective.

INTRODUCTION

Tissue engineering of the urinary bladder underwent progress during the last two decades. The constant development of stem cell biotechnology and material science provides new opportunities to translate experimental methods of bladder regeneration into clinical applications.

Urinary diversions based on urinary bladder wall replacement with bowel remain the gold standard despite associated complications, including stricture and fistula formation, and the development of metabolic disorders.

This proposed strategy has been routinely applied for over a century since it first was proposed. Due to the appropriate mechanical endurance, accessibility and anatomical vascularization of the intestinal wall, it is a justified choice for bladder reconstruction. Nevertheless, established surgical techniques are reaching their limits in terms of a functional result that might be improved upon by gradual implementation of tissue engineering solutions. Ability to restore complex histological structures of the bladder wall with integrated epithelial, neural, and muscle components offers a superior treatment over currently available solutions. In this context, regenerative medicine should be a natural developmental path of urinary bladder reconstruction and as such, should gain attention of, and support from the urological community.

Despite the promising announcement of in vivo urinary bladder reconstruction by Atala et al., there has been a lack in commercialization of therapies based on current investigations [1]. This is due to numerous obstacles that are slowly being identified and precisely overcome. A goal of regenerative medicine is to develop new concepts suitable for bladder regeneration that use biomaterials and stem cells. Our review provides a brief presentation of data regarding experimental bladder regeneration. We also highlight the obstacles that delay the introduction of regenerative medicine into clinical practice.

Tissue Engineering of the Urinary Bladder, for Whom and When?

As the field of tissue engineering advances, the reality of replacing a diseased urinary bladder is...
becoming a possibility. Before the introduction of this technology into the clinic, a need to identify objectives and specific contra indications justifying the tissue engineering approach is required.

Dividing urinary bladder disease into malignant and benign may be an indicator for replacement. Primary patient populations potentially suitable for tissue engineered urinary diversion have been identified by the authors (Fig. 1). These include the management of bladder cancer, neurogenic bladder conditions that threaten renal function, severe injury to the bladder due to radiation, intractable incontinence in females and chronic pain syndromes, and young patients with high-pressure-low-compliant bladders due to congenital anomalies such as bladder extrophy and myelomeningocele, which usually requires augmentation cystoplasty at the early stage of treatment.

Worldwide, urothelial bladder cancer is the ninth most common malignancy and 13th most common cause of cancer death [2]. During 2017, an estimated 75,000 patients will be diagnosed with bladder cancer, corresponding to 5% of the annual cancer cases [3]. Thus, bladder cancer is a major public health concern, hence, available therapies require continuous improvement. This is clearly demonstrated in the treatment of invasive bladder cancer, where the urologists must reconstruct the urinary tract after cystectomy and account for risk factors as well as the quality of life (QoL) after surgery in the patients. Worldwide, 95% of cystectomies performed are due to the diagnosis of invasive bladder cancer [4].

The choice of strategy for the treatment of bladder cancer depends on the presence of muscle wall infiltration. Approximately 70%–80% of the most common lesions are identified in the urothelium (pCIS), mucosa (pTa), or lamina propria (pT1), which are managed with bladder-sparing treatments and rigorous surveillance due to recurrence and being at risk of progression to higher-stage disease [5]. In contrast, tumors invading the muscularis propria (pT2 or higher disease), require complex oncological management, that is, radical cystectomy (RC) [6]. A particular group of pT1 patients with recognized high-risk features [i.e., multifocality, recurrence after intravesical therapy, extensive lamina propria invasion, and concomitant carcinoma in situ (CIS)] are at considerable risk for disease progression and benefit in the short-term from early radical management [7].

RC carries a significant risk of short- and long-term complications. Despite improved patient selection, anesthetic, surgical refinements, and perioperative care, RC remains a technically challenging procedure [8]. Routinely offered to oncological patients is the replacement of resected urinary bladder with orthotopic neobladder or conduit. These are the most frequently performed urinary diversions [9]. Robot assisted surgery can perform total intracorporeal urinary diversion with lower risk of complications but with comparable functional outcomes to other open techniques [10]. Notwithstanding this invasiveness reduction, explosion opening and detubularization of the bowel segment is a requirement of the procedure. This is recognized to be a major factor in determining high complication rates, especially in older patients [11]. To date, the usual solutions involve using segments of intestine. Although these sophisticated surgical techniques restore the proper function of reconstructed urinary tracts, they may increase the risk of stricture and fistula formation, and the development of metabolic disorders [12].

From the early clinical attempts at the beginning of the century, the bowel wall has been routinely used to restore urinary tract continuity after cystectomy. This solution is a compromise between the intestine’s biomechanical characteristics; suitable for urine storage and the risk for metabolic disorders related to a different histological structure. Chronic diarrhea, malabsorption syndromes, that is, such as vitamin B12 deficiency, electrolyte abnormalities including hyperchloremic metabolic acidosis, or hypokalemia, hypocalcemia, and hypomagnesemia are one of the main reasons for diminished QoL after urinary diversion [13].
Depending on the bowel segment used, the length of the bowel segment and the type of diversion, these metabolic consequences will be more or less pronounced. In older patients with reduced body compensation, the ability of these disorders might even endanger patient lives. Thus, side effects of known urinary diversion techniques are the major argument for pushing forward tissue engineering research focused on urinary tract regeneration.

Reconstructive urologic surgeons consider continent orthotopic neobladder replacement as the most favorable in terms of QoL for patients. This is because of the ability to void naturally via the native urethra and the undisturbed body image [14]. Nonetheless, based on literature, it remains unclear if this approach does in fact guarantee a better QoL for patients. Interestingly, even though using urostoma massively reduces the patient’s QoL, having a neobladder was not proven to display better QoL [15]. Studer et al., who developed and popularized orthotopic ileal neobladder, reliably demonstrated positive results for the long-term follow-up functional aspects for the procedure [16, 17]. Ten years after the initial surgery, 96% of their patients could void spontaneously. Studer et al. explained their outcomes through rigorously developed proactive postoperative management that was difficult to comply with in other centers [18]. Tissue engineering of the urinary bladder aims to provide a treatment method based on research and then commercialized bioengineered grafts. This strategy holds promise to provide replicative, highly standardized and characterized therapy worldwide. Hence, the clinical endpoint of this group of patients will also gradually become more important in context of this speculative paragraph, the expected constitution of regenerative medicine in urology may contribute to the recognition of new indications for total cystectomies. In the light of new abilities to regenerate or replace urinary bladders with a great functional result, decisions on treatment for benign bladder conditions will prioritize this approach. The concept of “preventing cystectomy” in patients with noninvasive bladder cancer could also be hypothetically established and gain importance.

**Urinary Conduit Construction**

The first experimental attempt to create a conduit urinary diversion with a tissue engineering approach was performed in 2007 on a rat model. In this study, SIS was used as scaffold, and seeded fibroblasts were intended to enhance the graft’s biocompatibility [22]. Five years later, a research team from The Netherlands published a similar strategy with a different scaffold material (Collagen type I with Vyproll mesh) on porcine model [23]. In both studies, no differences between seeded and unseeded scaffold were observed. Studies performed later showed superiority of scaffolds (Bladder acellular matrix [BAM]; polyglycolic acid [PGA]/poly(lactic-co-glycolic acid) [PLGA]) seeded with cells over the acellular ones [24, 25]. The major leverage of tissue engineered conduit over neobladder is its less complex structure that can be obtained with available techniques.

Despite initial reports which failed to demonstrate the necessity of using a cell based approach, results from studies on induced regeneration of tubular organs like ureter, urethra, or blood vessels indicated better regeneration outcomes within cell seeded constructs [26]. Soon, there will be a chance to receive the final answer which strategy is more efficient and should be translated into clinics. The research group who tried to reproduce results published by Atala et al. in 2006, registered a study entitled “Incontinent urinary diversion using and autologous neo-urinary conduit” (NCT01087697) [27]. Artificial urinary conduit was designed to be created form biodegradable a PGA/PLGA mesh seeded with fatty tissue derived smooth muscle cells. The most interesting part of this study included the evaluation of these artificial conduits during the clinical trial. The study’s status is “completed,” and we are now awaiting results that may open up a new clinical application perspective for tissue engineering.

**Tissue Engineering for Urinary Bladder; Current Status**

Two major approaches of tissue or organ regeneration by tissue engineering include the use of acellular and cellular scaffolds. The acellular scaffold approach involves either natural or synthetic biomaterials that stimulate the in vivo spontaneous regenerative process by serving as a solid support for the in-growth of the patient’s native cells. The cellular scaffold approach involves biomaterials and patient’s autologous cells to create neo-tissue in vitro. Generated neotissue is implanted back into the patient in order to complete the regeneration process in vivo.

To date, urinary bladder reconstruction utilizing tissue engineering techniques, have been used in 141 patients (Fig. 2). Both acellular (n = 124) and cellular (n = 17) scaffolds were used. The
most common indication for urinary bladder reconstruction was cancer and neurogenic dysfunctions (Fig. 3).

The first clinical studies that can be considered as prototypes for research on urinary bladder regeneration were performed in the 1950s and 1960s [28–30]. Plastic urinary bladder substitutes were implanted orthotopically into 34 patients following cystectomy for several weeks and removed after covering with fibrotic tissue. The generated “pseudo-bladder” experienced reduced capacity over time. High mortality and postoperative complications associated with the use of the plastic urinary bladder substitutes were a cause of discontinuation for this procedure. A very important fact regarding urinary bladder reconstruction was revealed during these clinical trials: acellular scaffolds allow for spontaneous regeneration of the urothelium but not smooth muscles.

Other biomaterials that have been used for urinary bladder reconstruction were gelatin sponge (n = 9), Japanese paper (n = 17), formalin preserved dog bladder (n = 12), lyophilized human dura (n = 44), bovine pericardium (n = 1), and small intestinal submucosa (n = 5) [31–39]. These biomaterials provided a temporary scaffold for tissue growth, underwent remodeling and degradation over time. A frequently observed complication in these patients was progressive decrease in urinary bladder capacity. These biomaterials were not used in any future studies despite good clinical outcomes observed in some patients.

Numerous experimental studies have demonstrated that functional bladder tissue can only be created by cell based approaches [40, 41]. The first clinical study on urinary bladder reconstruction with a cell seeded scaffold was performed by Atala et al. [1]. BAM or collagen-polyglycoic acid (C/PGA) composite scaffold seeded with autologous urothelial and smooth muscle cells were used for augmentation in seven cystoplasty patients with end-stage bladder disease due to myelomeningocele. For this purpose, urothelial and smooth muscle cells were isolated from small 1–2 cm² bladder biopsies, expanded for 7–8 weeks and seeded into 70–150 cm² of BAM or C/PGA scaffold at a density of 50 × 10⁶ cells per cm². The grafts were implanted with or without an omental wrapping. The bladders augmented with the composite scaffolds seeded with cells showed improved bladder compliance and increased capacity. Bladder biopsies performed at 31 months postoperatively revealed a proper three-layered structure of reconstructed bladders. In addition, no adverse events were observed. In contrast, more extensive fibrosis and limited regeneration were observed in bladders reconstructed with BAM. For the BAM group, it should be noted that there was no omental wrapping of reconstructed bladders in three out of four patients.
Therefore, it is unknown if the limited regeneration observed in this group were due to the use of a BAM scaffold or lack of omental wrapping. This study demonstrated that bladders tissue engineered with autologous cells seeded on C/PGA scaffolds with omental wrapping can be used for patients requiring cystoplasty [1].

Unfortunately, the recent publication by Joseph et al. was not able confirm these results [42] using an autologous cell seeded polyglycolide/polylactide (PGA/PLA) composite scaffold for augmentation cystoplasty in 10 patients with spina bifida. There was no clinical or statistical improvement in patient bladder capacity at 12 or 36 months. Serious adverse events of bowel obstruction and/or bladder rupture occurred in four patients. At the time of publication, five of the patients underwent or were scheduled for traditional cystoplasty. Although these two clinical studies were comparable in design and used the same clinical background, and cell types, the variability in cell number, biomaterial type, or graft surface area might have influenced the outcomes (Table 1). Therefore, further investigations are required to confirm both safety and efficiency of tissue engineered grafts for augmentation cystoplasty.

Table 1. Clinical studies using cell seeded grafts for human urinary bladder regeneration

| Indication for augmentation cystoplasty | Atala (2006) | Joseph (2014) |
|----------------------------------------|-------------|--------------|
| Number of patients                     | 4           | 3            |
| Patients age (years)                   | 4–19        | 4–19         |
| Indication for augmentation cystoplasty | Neurogenic bladder myelomeningocele | Neurogenic bladder myelomeningocele |
| Biomaterial                            | BAM         | C/PGA        |
| Type and number of cells               | UCs (5 × 10^6/cm^3) SMCs (5 × 10^6/cm^3) | UCs (5 × 10^6/cm^3) SMCs (5 × 10^6/cm^3) |
| Omental wrapping, number of patients  | 1           | 3            |
| Bladder cycling technique              | Yes         | Yes          |
| Follow-up (months)                     | 22–61       | 22–61        |
| Postoperatively increased bladder capacity | No         | Yes          |
| Postoperatively improved bladder compliance | No         | Yes          |
| Adverse events                         | No adverse events | No adverse events |
| Conversion to traditional ileocystoplasty, number of patients | 0           | 0            |

Abbreviations: BAM, bladder acellular matrix; PGA, polyglycolic acid; PL A, polylactic acid; SMCs, smooth muscle cells; UCs, urothelial cells.

Specific urinary tract cellular stress factors (urine, reduced blood perfusion, pathogens) makes the urinary bladder environment unfavorable for induced regeneration. Urine was proven to be one of the most influential factors that determined survival of implanted cells. In vitro studies carried out on urothelial cells and mesenchymal stem cells (MSC) with urine exhibited extreme cytotoxicity [43, 44].

Cells seeded on a scaffold facing toward to the bladder lumen are directly exposed to stored urine, especially those located within inner biomaterial surface [21]. Urine is rich in cationic substances, protamine sulfate and low molecular weight products that are mainly responsible for its high and nonselective cytotoxicity. When the protective uroplakin barrier is dysfunctional, as it is during early stages of urothelium regeneration, cytotoxic agents bind spontaneously to the anionic milieu of inner layers of the bladder mucosa. Thus, deep penetrating urine is believed to exert a significant impact on the survival of implanted stem cells [45]. Since urine has a harmful effect on the cellular components of a tissue engineered bladder, it is important that the scaffold has adequate permeability since it might partially act as an isolation barrier. On the other hand, low porosity scaffolds have excellent resistance against fluid penetration and may prevent urine leakage from the graft, however, low porosity scaffolds inhibit seeded cell migration [46].

Interestingly, voided urine turned out to be a source of so-called urine-derived stem cells [47, 48]. After isolation and expansion of this cell type, it was used for urinary-tract regeneration [49]. The influence of urine on urine-derived stem cells after in vitro expansion has not been investigated yet; however, considering their origin, they must be more resistant to urine than other cell types. Investigation of the mechanism behind this possible resistance might be very useful to increase cell surveillance after implantation.

Many studies have confirmed the contribution of cells in bladder regeneration [50, 51]. Diverse acellular scaffolds were found to be suitable only for regeneration of small defects using experimental models. From a clinical point of view, this is of no importance. In these cases, regeneration of the damaged area or an area of the resected bladder could be obtained by cells migrating from the surrounding native tissue under normal responses to tissue injury. Regeneration was observed mainly at the anastomosis edges of implanted grafts that were applied for augmentation in larger defects of the urinary bladder wall. Whereas the middle portion of the grafts were covered by overgrown fibrotic tissue [52]. Cell seeded bioengineered grafts are believed to be more efficient at regenerative induction of the urinary bladder wall in comparison to biomaterial alone. Stem cells are an indispensable tool to modulate the host healing process resulting in gradual graft remodeling that finally may lead to regrowth of a layered structure of the neo-bladder wall. Factors determining the restoration of the neo-bladder’s mechanical endurance and protection...
against urine are the regeneration process rate and efficiency [53]. Highly advanced stem cell strategies addressing bladder regeneration are still under development. MSC, adipose stem cells, hair follicle stem cells, and stem cells derived from amniotic membrane were evaluated for this purpose; however, none were reported to have a specific superiority over another particular cell type [54]. Therefore, MSC has become the most commonly applied stem cell of choice due to an abundance of niches, and well-established isolation and in vitro propagation protocols [55]. A number of different processes that determine regenerative outcomes were documented to be regulated by various MSC paracrine factors. Production and release of angiogenic factors such as VEGF and Ang1/Ang3 stimulates neovascularization and induces maturation of the newly regenerated area [56]. Our previous work indicated that MSC upregulated anti-inflammatory cytokines, that is, IL-10 and Transforming Growth Factor beta (TGF-β), while simultaneously attenuating pro-inflammatory signals (IL-1α, IL-6, Transforming Growth Factor alpha [TGF-α], Interferon gamma [INF-γ]) [50]. Apart from MSC, differentiated smooth muscle and urothelial cells were often evaluated for urinary bladder regeneration. These cells derived from bladder biopsy were successfully used for the regeneration of high-pressure or poorly compliant bladders [1]. A priori diseased cell source is a major limitation of autologous differentiated cell lines isolated from urinary tracts. Abnormal growth of isolated MSC was observed with less contractile ability and inferior adherence in neuropathic bladder dysfunction [57]. Interstitial cystis, posterior urethral valves, epispadias, non-neurogenic bladder dysfunctions, and other bladder conditions also reduce the proliferative capacity of isolated cells [58]. The major disadvantage of bladder biopsy cells is the contraindications to use them for cell-based management in patients with urothelial cancer. Isolated urothelial cells harboring activated oncogenes increases the risk of tumor formation within tissue engineered neo-bladders due to the panurothelial nature of bladder cancer [59]. Concentrating research efforts on MSC bladder regeneration will overcome this problem. These cells can be isolated from amniotic fluid, Wharton’s jelly or the hair follicle; however, due to the availability and the ability of sufficient cell generation, bone-marrow and adipose tissue are the most commonly used sources in bladder regeneration [60]. MSC have the ability to differentiate into multiple cell types, including urothelial and smooth muscle cells [61, 62]. Use of MSC for bladder regeneration includes the expansion of the cells and implantation with or without predifferentiation. Differentiation can be performed before or after scaffold seeding using a conditioned or chemically defined culture medium [63]. Smaller defects do not require stem cell predifferentiation in vitro because after implantation into the bladder microenvironment, the cells can undergo differentiation into the desired cell type in vivo under the influence of trophic factors secreted by the urothelial and smooth muscle [64].

Whole bladder regeneration is more complex; stem cell predifferentiation could help in the restoration of bladder structure, but the differentiation efficiency is very low and the mechanism of this process is still unclear. In addition, little is known about the phenotypic stability of stem cell-derived urothelial and smooth muscle cells following implantation [65].

In most studies, the fate of cells seeded onto scaffolds and implanted into bladders is unknown. Our unpublished data has revealed that only a small number of implanted cells stained positively with PKH-26 remained in the regenerated area after 3 months follow-up. Another important issue is the cell seeding density onto the scaffold. In the same study, we determined that significantly better results can be obtained when higher cell seeding densities (4 × 10⁶/cm² vs. 10 × 10⁶/cm²) onto the scaffold were used. Thus, the cell number is a crucial factor for determining the regenerative outcome.

Determinants for successful urinary bladder regeneration using tissue engineering techniques are the selection of a suitable cell source, use of optimal cell density, and elaboration of efficient stem cell differentiation techniques.

**CHALLENGES FOR FUTURE TRANSLATION INTO CLINIC - THE NEED FOR SYSTEM THINKING**

The ultimate aim of tissue engineering is to grow an in vitro living urinary bladder that can replace a native one [59]. The realization of this goal must be postponed until biotechnology has reached an appropriate level of development. At present, tissue engineering tries to establish an optional solution for patients needing bladder replacement. At this initial stage of translational research, it is crucial to organize collaborative teams of research scientists and clinical urologists to support multidisciplinary insights at each step of future therapy development [66]. This approach should allow us to reduce research costs, better address patients’ needs, and prevent us from pursuing any potential dead ends. Urology is one of the fastest growing segments in the tissue engineering market, which is rapidly expanding to be worth $11.5 billion by 2022 [67].

Translation of tissue engineered based therapies into urology should be conducted using cooperative infrastructure consisting of tissue engineering facilities and urological departments. Synchronization of cell culturing with biomaterial scaffold fabrication requires an establishment of well-coordinated procedures. Formation of tissue engineering departments belonging to urology clinics may be leveraged in similar way as the cell-transplantation units of hematology-oncology. This organizational set-up combining stem cell harvesting, culturing, and transplantation has been proven to be safe and therapeutically efficient.

Quality control of the biomaterials used in various surgical applications is a key challenge for the tissue engineering industry. Tissue engineering based approaches are classified as advanced medical therapy, which needs to be authorized through central agencies [68]. The European Union institutions agreed on a regulation on advanced therapies coordinated by European Medicines Agency [69]. Analogously, in U.S., the Center for Biologics Evaluation and Research (CBER) regulates cellular and biomaterial based therapies. CBER uses both the Public Health Service Act, and the Federal Food Drug and Cosmetic Act as enabling statutes for oversight [70].

Tissue engineered based solutions for urinary bladder replacement consist of biomaterial and cellular components that are subject to detailed certification in order to meet good manufacturing standards. Therapy evaluation comprised, inter alia, the manufacture of biomaterials in vitro cell culture, scaffold seeding, demonstration of conserved mechanical properties, and safety/efficacy in adequate animal models. Efforts in the future will most likely focus on increasing the safety of tissue engineered products. Strict regulations on translating new bladder replacement modalities into the clinic are necessary in the lights of best clinical practice. Nevertheless, with too many bureaucratic and time-consuming burdens/procedures, we risk successful lab research and new findings rarely being translated into clinical practice.
Mechanical Properties
In the field of the urinary bladder regeneration, the graft’s mechanical behavior corresponding to the native one is particularly important [71]. The mechanical characteristic of an intact bladder wall should be taken as a benchmark in efforts to construct a tissue engineered bladder. Nevertheless, we need to take into account that the urinary bladder’s standard mechanical properties are resultant of passive and active behavior, and dynamic changes during the emptying and filling phase. Designing and fabricating biomaterial which could mimic these sophisticated biomechanical properties is limited by available technology [21]. Alternatively, the mechanical properties of the bowel wall which are applied during reconstructive urology as a gold standard can be considered as a starting point for ongoing research. Following this idea, we should aim to produce a graft with mechanical features that would in fact reflect improved parameters of the bowel wall, adopted for the specific environment of urinary tracts. Such a biomaterial that would be superior to the bowel wall would become a new gold standard in reconstructive urology.

Artificially designed scaffolds for urinary bladder replacement should be endurable on low but continuous volume changes, lacking the tendency to repeated kinking, especially with downward abdominal pressure and subsequent obstruction [72]. Major difficulty during preoperative scaffold evaluation is predicting how the regenerating tissue affects the biomaterial matrix remodeling after implantation. The graft should obtain the intended mechanical characteristics after completed neo-tissue formation. Hence, tensions generated by connective tissue and regenerated muscle cells need to be taken into consideration in planning the final graft structure [73].

Considering the urinary tract’s hydrodynamic features, matters of concern are potential determinants of long-term biomechanical fatigue, that is, continuous flow and related volume extensibility during the storage phase. Before implementation, a fatigue test could easily reveal the durability of the fabricated neo-tissue; however, no published studies characterized fatigue in the preclinical tissue engineered graft [74]. Of utmost importance in reconstructive therapies dedicated to young patients with a long-life expectancy is fatigue analysis.

A well-functioning bladder substitute should contain less than 100 ml urine after voiding. A residual urine volume of less than 100 ml was proven not to increase the risk of ascending infection [75]. The physiological background of the neobladder in terms of elasticity and compliance suggests that the biomechanical specification would be challenging. Resultant parameters of biochemical specification during the storage phase should provide conditions to reversibly increase the bladder capacity up to 500 ml several times a day. The neobladder needs to sustain a constant low renal pelvic pressure as a main generator of ureteral back pressure. Urinary tract obstruction was the leading cause of long-term renal function impairment, regardless of whether the patient had ileal conduit diversion or orthotopic ileal neobladder [76].

The mechanical properties of an in vitro constructed neobladder are determined by the biomaterial and cellular components. Preclinical studies comprised of research involving animal models and bioreactors are required in order to obtain optimal mechanical characteristics for the tissue engineered bladder wall. Using this concept, a urinary tract-specific physiological environment can be provided during neotissue maturation, ultimately improving data collection to better plan the clinical setting.

Vascularization
For adequate clinical use, a tissue engineered urinary neobladder should have a minimal capacity of approximately 100 ml. Consequently, if the topography of the neobladder is considered to be the irregular sphere, it would be an area of about 130 cm² and a thickness of several millimeters.

Available biomaterial and cell culturing technologies provide solutions to engineer cell seeded scaffolds that fulfill the objectives of structural design. However, a major hurdle in growing neo-organs lies in the formation of vascular networks capable of perfusing regenerating tissue after implantation [77].

The wall of the neobladder needs to be prevascularized to avoid graft necrosis since diffusion alone is not sufficient to maintain tissue oxygenation. In order to obtain sufficient functional results, an abundance of vascular networks is required to guarantee blood supply to metabolically active bladder walls rich in muscle [78]. A recognized cause of continual bladder loss of function is the deteriorated microvasculature [79].

Although spontaneous vasculogenesis and angiogenesis take place after biomaterial implantation, these processes are not effective and fast enough to become a reliable option in terms of therapeutic application [80]. Attempts to stimulate vascularization by enriching implants with pro-angiogenic factors, that is, vascular endothelial growth factor (VEGF), matrix metalloprotease (MMP), basic fibroblast growth factor (bFGF), platelet derived growth factor (PDGF), angiotsenin (Ang), and hepatocyte growth factor (HGF) have demonstrated limited use due to the time-consuming nature, and the possible lack of ability to shape the growing vascular network architecture [81]. One promising approach is prevascularization of a tissue construct with networks of well-formed capillaries prior to transplantation. In order to achieve this aim, the best choice at present is de novo design and generation of the vascular network with the use of a customizable three-dimensional (3D) bioprinting technology [82]. Bertassoni et al. developed technology that prints a template using agarose fibers to fabricate microchannel networks that can be populated with endothelial cells [83]. Capturing the normal architecture of a bladder wall and applying it as a template for the fabrication of a collagen-based vascularized scaffold is possible in the long term, as recently demonstrated by Huling et al. [84]. Attention should be focused on the characteristics of lower urinary tracts during vascular network design for any bladder substitution. With regards to these requirements, the arrangement of an artificially created vascular network must allow blood vessels to maintain patency and guarantee network sealing during wall stretching of the neobladder.

During partial bladder reconstruction, vascularization of scaffold could be achieved by alternatively implanting scaffolds into areas of the body of favorable local conditions for neo-vascularization. Following this idea, the peritoneal cavity might serve as a natural bioreactor [85].

Following the critical stage after implantation of the prevascularized neobladder is to perform anastomosis with arterial and venous blood vessels in the host. Vascular network inosculation should take place within several minutes in order to increase cell survival and prevent necrosis [86]. This pivotal problem is still waiting to be addressed by any methodology, nevertheless, urological surgeons would certainly prefer grafts that provide sutureable vascular pedicles.

In regenerative medicine, we might use the opportunity to use pharmacodynamics for purposes other than those originally
intended. Accordingly, well known PDE5 inhibitors for the treat-
ment of erectile dysfunction might be useful in tissue engineer-
based reconstructive urology because of their pro-angiogenic
activity. In a small animal model, orally administrated PDE5 inhibi-
tors facilitated the recruitment of endothelial progenitor cells
from the blood and bone marrow, and contributed to the promo-
tion of new capillary formation within the neobladder [87].

Fibrotic Reaction
Implantation of a biomaterial into the body always triggers foreign
body response [88]. This process is step-wise, maintained by over-
lapping prolonged inflammation and wound healing, which drives
gradual fibrotic encapsulation of the engrafted biomaterial. Con-
sidering a neobladder, the foreign body’s surface will range from a
to tens of hundred square centimeters and as such, presents
a risk of triggering extensive local scarring.

Fibrous tissue overgrowth first limits in vivo functionality and
longevity of implantable constructs [89]. Second, extensive local
fibrosis would be likely initially spread in the pelvis and gradually
ascend into the peritoneal cavity, resulting in severe adhesion
formation.

Abdominal adhesions are related to chronic abdominal pain
and might cause potentially life-threatening situations, including
mechanical ileus and bowel necrosis [90].

Alterting the fibrotic response toward an engineered neoblad-
er will not be a straightforward task. Different concepts to allevi-
ate excessive tissue response have been proposed. Given the
exposed mosaic signaling architecture regulating progression of
fibrosis, a number of potential targets have been described [91].
Multifactorial regulation is a major challenge. Selective targeting
of TGF-ß as a factor pathway failed to hamper the fibrotic reaction
in the clinical setting [91–93]. Similarly, unsuccessful attempts to
use IFN-gamma endothelin agonist or antagonists of IL-17 as an
anti-fibrotic treatment demonstrated the necessity for coordi-
nated suppression of more than one pro-fibrotic cascade [94–96].

From a urologist’s perspective, the most efficient first line
therapy overcoming biomaterial related fibrosis would be a phar-
macological one. Despite rich experience in antifibrotic treatment,
mainly gained from research on pulmonary fibrosis, there are a
few management options which could affect the formation of a
fibrous capsule around a neobladder. Pirfenidone, a medication
with multidirectional antifibrotic action, might be appropriate as a
perioperative treatment after performing urinary diversion with
the use of biomaterials [97]. Steroid and nonsteroid drugs slowed
down pathologic-fibrosis in many clinical settings. Unfortunately,
since these agents may influence the behavior of cancer cells,
they must be avoided until proper clinical evaluation is conducted
[98].

Most research data is generated by analyzing disease related
pathological fibrosis, but elective implantation of a neobladder
has advantages that should be exploited further. First, planned
procedures give opportunity to intervene from the very begin-
ning and counteract the activation of fibrotic mechanisms. Second,
anti-fibrotic agents could be incorporated within an implanted
scaffold, which may exert a strong local impact on the host healing
process. Alternatively, developing a minimal invasive laparoscopic
or robotic extraperitoneal technic of graft implantation might also
limit perioperative site scarring and reduce the risk of severe
abdominal adhesion.

Innervation
Lower urinary tracts are innervated with cholinergic, peptidergic,
and nitregeric nerve fibers of peripheral autonomic and somatic
nerve systems [99]. Balanced interplay between the activity of
these neuronal networks regulate a proper bladder function.
According to the principles of artificial organ engineering, the res-
toration of bladder innervation might be achieved by regeneration
of neuronal components and shaping of the neuronal network, or
by replacing it with an artificially designed material [100]. The
solution of this important problem was, however, hardly ever
highlighted in experimental settings [101]. We are currently
focused on inducible regeneration of the urethelial and smooth
muscle layers that alone do not guarantee proper bladder func-
tion. During further research, the need for neuronal network sub-
stitute will emerge to re-establish ascending and descending
neuronal transmission as well as autonomic neobladder activity.

Tissue engineering has developed technology to culture neu-
rons that might be applied in attempts to create an artificially
designed neuronal network within the neobladder wall.

Ma et al. provided one of the first reports demonstrating that
neural progenitor cells cultured in 3D matrix spontaneously recap-
itated functional synapses [102], Ban et al. proved that culti-
vated neurons preserved the capacity of generating signal
transduction networks [103]. The major obstacle, however, is to
constitute a cell source in the human body from where neuronal
cells could be extracted without harm. An interesting strategy
with translational potential is to harvest neuronal precursors by
stereotactic biopsy from niches in adult central nervous system
(CNS) with preserved neurogenesis [104]. Alternatively, a variety
of stem cells might be considered for differentiation into neurons
as it has been already proposed [105, 106].

To be consistent with the above-proposed scenario, forming a
neuronal network might be guided by biochemical, biophysical,
and topographical signals provided by a scaffold that could be
individually rendered by neuronal modeling experts. Moe et al.
used a customizable multi-architecture chip based on Polydime-
exy/siloxane that could control differentiation of neuronal progeni-
tor cells [107].

Although de novo regeneration of a convolutional neural net-
work within an artificial urinary bladder is far beyond tissue engi-
neering technology, this difficulty can be approached differently.
Biocompatible current conductive material might be applied as a
replacement for a neuronal network in order to propagate action
potentials generated in computer-controlled implantable stimula-
tor. This computer unit would additionally couple signaling
between the neobladder and the host’s neuronal system. It
should also be noticed that further advances in a tissue engi-
neered graft innervation are inherently dependent from research
on urinary bladder neurohistology which still needs to be better
de ned.

THE MICROENVIRONMENT OF TISSUE ENGINEERED GRAFT

Tissue engineered urinary diversions are inspired by the biology of
urinary tracts. The biomimetic approach aims to create a graft
milieu that is similar to the physiological environment of the
developing tissue [108]. The basis of this strategy is to speed up
graft intake in a positive manner and to induce subsequent
remodeling. The microenvironment of the tissue engineered graft
is built from two inherent components: cellular and biomaterial
that both interfere with the host systems [109]. Before implanta-
tion, cell seeded grafts grown in incubators with strictly controlla-
ble surroundings provide cultivated cells an optimal microenvi-
ronment. After implantation, these cells are suddenly expo-
sed to a much more complex microenvironment laden with pro-
inflammatory mediators and activated immunoreactive cells
[110]. In this scenario, the microenvironmental niche should play
a supportive role for the self-renewal, survival, and differentiation
of the applied cell populations, and act as a shield to damaging
factors. Thus, tissue engineering methods should provide a stable
cell-friendly microenvironment to engrafted cells after implanta-
tion [111]. The response on this requirement could be a cocoon
like architecture of the biomaterial matrix that protects the graft’s
cellular component from damaging agents. Coupling of immuno-
modulatory agents to biomaterial scaffolds might change them
into “immunomodulating” biomaterials that could actively shape
host response [112]. Hypothetically, along with the better under-
standing of paracrine signaling pathways it could be possible to
guide behavior of host immune cells and direct them to support
graft intake.

SUMMARY

Tissue engineered grafts designed to replace urinary bladder will
become in future new gold standard of reconstructive urology.

REFERENCES

1 Atala A, Bauer SB, Soker S et al. Tissue-engineered autologous bladders for patients needing cystoplasty. Lancet 2006;15:1241–
1246.
2 Dobruch J, Daneshmand S, Fisch M et al. Gender and bladder cancer: A collaborative review of etiology, biology, and outcomes. Eur Urol 2016;69:300–310.
3 Troussard G, Shariat SF, Dragomir A et al. Conditional survival after radical cystectomy for bladder cancer: Evidence for a patient changing risk profile over time. Eur Urol 2014;66:361–370.
4 Takenaka A. Current status of robot-assisted radical cystectomy: What is the real benefit? Yonog Acta Med 2015;58:95–99.
5 Alfred Witjes J, Lebret T, Compérat EM et al. Updated 2016 EAU guidelines on muscle-invasive and metastatic bladder cancer.
Eur Urol 2017;71:462–475.
6 Witjes JA, Compérat E, Cowan NC et al. European Association of Urology. EAU guidelines on muscle-invasive and metastatic bladder cancer: Summary of the 2013 guidelines. Eur Urol 2014;65:778–792.
7 Jäger W, Thomas C, Haag S et al. Early vs delayed radical cystectomy for ‘high-risk’ carci-
noma not invading bladder muscle: Delay of cystectomy reduces cancer-specific survival. BJU Int 2011;108:E284–288.
8 van Hemelrijck M, Thorstensen A, Smith P et al. Risk of in-hospital complications after radical cystectomy for urinary bladder carci-
noma: Population-based follow-up study of 7608 patients. BJU Int 2013;112:1113–1120.
9 Clifford TG, Shah BH, Bazargani ST et al. Prospective evaluation of continent following follow-up study of 7608 patients. BJU Int 2013;112:1113–1120.
10 Ahmed K, Khan SA, Hayn MH et al. Analysis of intracorporeal compared with extracorporeal urinary diversion after robot-assisted radical cystectomy: Results from the International Robotic Cystectomy Consortium. Eur Urol 2014;65:340–347.
11 Buscarini M, Pasini E, Stein JP. Complications of radical cystectomy. Minerva Urol Nefrol 2007;59:67–87.
12 Vasdev N, Moon A, Thorpe AC. Meta-
bolic complications of urinary intestinal diver-
sion. Indian J Urol 2013;29:310–315.
13 Krajewska W, Piszczek R, Krajewska M et al. Urinary diversion metabolic complications—underestimated problem. Adv Clin Exp Med 2014;23:633–638.
14 Park J, Ahn H. Radical cystectomy and orthotopic bladder substitution using ileum. Korean J Urol 2011;52:233–240.
15 Singh V, Yadav R, Sinha RJ et al. Prospective comparison of quality-of-life outcomes between ileal conduit urinary diversion and orthotopic neobladder reconstruction after radical cystectomy: A statistical model. BJU Int 2014;113:726–732.
16 Zehnder P, Dhar N, Thurairajah R et al. Effect of urinary tract infection on reservoir function in patients with ileal bladder substitu-
tes. J Urol 2009;181:2545–2549.
17 Kassouf W, Hautmann RE, Bochner BH et al. A critical analysis of orthotopic bladder substi-
tutes in adult patients with bladder cancer: Is there a perfect solution? Eur Urol 2010;58:374–383.
18 Studer UE. Life is good with orthotopic bladder substitutes! BJU Int 2014;113:686–687.
19 Shariat SF, Milowsky M, Droller MJ. Bladder cancer in the elderly. Urol Oncol 2009;27:653–667.
20 Shariat SF, Sfakianos JP, Droller MJ et al. The effect of age and gender on bladder cancer: A critical review of the literature. BJU Int 2010;105:300–308.
21 Kloskowski T, Pokrywczynska M, Drewa T. Artificial urinary conduit construction using tissue engineering methods. Cent European J Urol 2015;68:109–114.
22 Drewa T. The artificial conduit for uri-
nary diversion in rats: A preliminary study. Transplant Proc 2007;39:1647–1651.
23 Geutjens P, Roelofs L, Hoogenkamp H et al. Tissue engineered tubular construct for urinary diversion in a preclinical porcine model. J Urol 2012;188:653–660.
24 Basu J, Jayo MJ, Ilagan RM et al. Regener-
ation of native-like neo-urinary tissue from nonbladder cell sources. Tissue Eng Part A 2012;18:1025–1034.
25 Liao W, Yang S, Song C et al. Tissue-
engineered tubular graft for urinary diversion after radical cystectomy in rabbits. J Surg Res 2013;182:185–191.
26 Sloff M, Simiaoforidis V, Tiemessen DMJ et al. Tubular constructs as artificial urinary conduits. J Urol 2016;196:1279–1286.
27 Kates M, Singh A, Matsuji H et al. Tis-
sue-engineered urinary conduits. Curr Urol Rep 2015;16:1–8.
28 Bohne AW, Urwiller KL. Experience with urinary bladder regeneration. J Urol 1957;77:725–732.
29 Portilla Sanchez R, Blanco FL, Santamarina A et al. Vesical regeneration in the human after total cystectomy and implan-
tation of a plastic mould. Br J Urol 1958;30:180–188.
30 Tsukikide A, Murvanidze D, Dvali R et al. Formation of a bladder by a plastic shell after total cystectomy. Br J Urol 1964;36:102–105.
31 Tsuj I, Kuroda K, Fujieda J et al. Clinical experiences of bladder reconstruction using

T.D. received honoraria as a Speaker for Astellas, Speaker for Bayer. The other authors indicated no potential conflicts of interest.

AUTHOR CONTRIBUTIONS

J.A. and M.P.: conception and design, manuscript writing; S.V.V.B. and T.K.: manuscript writing; T.D.: conception and design, manu-
script writing. administrative support.

DISCLOSURE OF POTENTIAL CONFLICTS OF INTEREST

314x618 can safely translate tissue engineering based solutions into recon-
structive urology.
preserved bladder and gelatin sponge bladder in the case of bladder cancer. J Urol 1967;98:91–92.

7 Tsuji, Kuroda K, Fujieda J et al. A clin- ical and experimental study on cystoplasty not using the intestine. J Urol 1963;89:214–225.

8 Oriksa, S, Tsuji I. Enlargement of con- tracted bladder by use of gelatin sponge blad- der. J Urol 1970;104:107–110.

9 Fujita K. The use of resin-sprayed thin paper for urinary bladder regeneration. Invest Urol 1978;15:355–357.

10 Taguchi H, Ishizuka E, Saito K. Cyto- plasty by regeneration of the bladder. J Urol 1977;118:752–756.

11 Kelami A. Duroplasty of the urinary bladder—results after two to six years. Eur Urol 1975;1:178–181.

12 Arikun N, O zdilier E, Yaman O et al. Aug- mentation durocystoplasty in neurogenic blad- der dysfunction. Int J Urol 1995;2:172–175.

13 Caione P, Boldrini R, Sarlono A et al. Bladder augmentation using acellular collagen biomatrix: A pilot experience in exstrophic patients. Pediatr Surg Int 2012;28:421–428.

14 Mohamed A, Akhtar DH, Jo IK et al. Bladder reconstruction using bovine pericardium in a case of enterovesical fistula. Korean J Urol 2011;52:150–153.

15 Yoo JI, Meng J, Oberpenning F et al. Bladder augmentation using allogenic bladder submucosa seeded with cells. Urology 1998;51:221–225.

16 Oberpenning F, Meng J, Yoo JI et al. De novo reconstruction of a functional mamma- lian urinary bladder by tissue engineering. Nat Biotechnol 1999;17:149–155.

17 Joseph DB, Borer JG, De Filippo RE et al. Autologous cell seeded biodegradable scaffold for augmentation cystoplasty: Phase II study in children and adolescents with spina bifida. J Urol 2014;191:1389–1395.

18 Davis NF, Calbana A, McGuire BB et al. Evaluation of viability and proliferative activity of human urothelial cells cultured onto xeno- genic tissue-engineered extracellular matrices. Urology 2011;77:1007–1007.

19 Adamowicz J, Klosowski J, Tkowerczewicz J et al. Urine is a highly cytotoxic agent. Does it influence on the stem cell therapies in urol- ogy. Transplant Proc 2012;44:1439–1441.

20 Rajasekaran M, Stein P, Parsons CL. Toxic factors in human urine that injure uro- thelium. Int J Urol 2006;13:409–414.

21 Klosowski T, Kowalczyk T, Nowacki M et al. Tissue engineering and ureter regeneration: Is it possible? Int J Artif Organs 2013;36: 392–405.

22 Zhang J, McNeill E, Tian H et al. Urine derived cells are a potential source for urologi- cal tissue reconstruction. J Urol 2008;180: 2226–2233.

23 Klosowski T, Nowacki M, Pokrywczyńska M et al. Urine- a waste or the future of regenerative medicine? Med Hypotheses 2015;84:344–349.

24 Wu S, Liu Y, Bharadwaj S et al. Human urine-derived stem cells seeded in a modified 3D porous small intestinal submucosa scaffold for urethral tissue engineering. Biomaterials 2011;32:1317–1325.

25 Pokrywczyńska M, Jundzill A, Bodnar M et al. Do mesenchymal stem cells modulate the milieu of reconstructed bladder wall? Arch Immunol Ther Exp (Warsz) 2013;61:483–493.

26 Lam Van Ba O, Aharon Y, Loutochn O et al. Bladder tissue engineering: A literature review. Adv Drug Deliv Rev 2015;62:393–37.

27 Dorin RP, Pohl HG, De Filippo RE et al. Tubularization urethral replacement with unseeded matrices: What is the maximum dis- tance for normal tissue regeneration? World J Urol 2008;26:323–326.

28 Kim JH, Lee SR, Song YS et al. Stem cell therapy in bladder dysfunction: Where are we? And where do we have to go? Biomed Res Int 2013;2013:930713.

29 Orabi H, Bouhout S, Morissette A et al. Tissue engineering of urinary bladder and ure- thra: Advances from bench to patients ScienceWorldJournal 2013;2013:154564.

30 J undzill A, Pokrywczyńska M, Adamowicz J et al. Vascularization potential of electrospun poly-L-lactide-co-caprolactone scaffold: The impact for tissue engineering. Med Sci Monit 2017;23:1540–1551.

31 Kusuda GM, Carthew J, Lim R et al. Effect of the microenvironment on mesenchy- mal stem cells paracrine signalling: Opportuni- ties to engineer the therapeutic effect. Stem Cells Dev 2017;26:617–631.

32 Lin HK, Cowan R, Moore P et al. Charac- terization of neoplastic bladder smooth muscle cells in culture. J Urol 2004;171:1348–1352.

33 Subramaniam R, Hinley J, Stahlischmidt J et al. Tissue engineering potential of urothe- lial cells from diseased bladders. J Urol 2011;84:1999–2004.

34 Adamowicz J, Kowalczyk T, Drewa T. Tis- sue engineering of urinary bladder—current state of art and future perspectives. Cent European J Urol 2013;66:202–206.

35 Drewa T, Adamowicz J, Sharma A. Tis- sue engineering for the oncologic urinary bladder. Nat Rev Urol 2012;9:561–572.

36 Yang B, Zheng JH, Zhang YY. Myogenic differentiation of mesenchymal stem cells for muscle regeneration in urinary tract. Chin Med J (Engl) 2013;126:2952–2959.

37 Liu J, Huang J, Lin T et al. Cell-to-cell contact induces human adipose tissue-derivedstromal cells to differentiate into urotheli- um-like cells in vitro. Biochem Biophys Res Com- mun 2009;390:931–936.

38 Tian H, Bharadwaj S, Liu Y et al. Differ- entiation of human bone marrow mesenchy- mal stem cells into bladder cells: Potential for urological tissue engineering. Tissue Eng Part A 2010;16:1769–1779.

39 Bury MJ, Fuller NJ, Meisner JW et al. The promotion of functional urinary bladder regeneration using anti-inflammatory nanofib- bers. Biomaterials 2014;35:9311–9321.

40 Pokrywczyńska M, Adamowicz J, Sharma AK et al. Human urinary bladder regeneration through tissue engineering—an analysis of 131 clinical cases. Exp Biol Med (Maywood) 2014;239:264–271.

41 Williams DF. 25 Tissue engineering: The multidisciplinary epiphenome of hope and despair. In: Paton R, McNeill E, Meisner JW. Studies in Multidisciplinary Medicine. Elsevier; 2005;3:483–524.

42 Anundhati Parmar Medical Device Busi- ness. Available at: http://www.mddionline.com/ article/tissue-engineering-market-be-worth-115- billion-2022. Accessed April 12, 2017.

68 Regenerative medicine and the regula- tion of advanced therapies medicinal prod- ucts. Available at: https://www.hta.gov.uk/ policies/regenerative-medicine-and-regulation-advanced-therapies-medicinal-products-atmps. Accessed April 12, 2017.

69 Multidisciplinary: Cell therapy and tissue engineering. Available at http://www.cema. europa.eu/ema/index.jsp?lang=C&coll=/home/ general_content_000405.jsp&mid=WCOB 01A058002958a. Accessed April 12, 2017.

70 About the Center for Biologics Evalua- tion and Research. Available at http://www. fda.gov/AboutFDA/CentersOffices/OfficeofMedi- calProductsandTobacco/CBER. Accessed April 12, 2017.

71 Miftakhov RN, Nam HG. Biomechanics of the Human Urinary Bladder. Springer 2013.

72 Kollhoff DM, Cheng EY, Sharma AK. Uro- logic applications of engineered tissue. Regen Med 2011;6:757–765.

73 Kheradmandi M, Vasheghani-Farahani E, Ghiaiseddin A et al. Skeletal muscle regener- ation via engineered tissue culture over electro- spun nanofibrous chitosan/PVA scaffold. J Biomed Mater Res A 2016;104:1720–1727.

74 Martin C, Sun W. Fatigue damage of collagenous tissues: Experiment, modeling and simulation studies. J Long Term Eff Med Implants 2015;25:55–73.

75 McNell SA, Hargreave TB, Gefraud- Ricouard C et al. Postvoid residual urine in patients with lower urinary tract symptoms suggestive of benign prostatic hyperplasia: Pooled analysis of eleven controlled studies with alfuzosin. Urology 2001;57:459–465.

76 Jin X, Roethlisberger S, Burkhard FC et al. Long-term renal function after urinary diversion by ileal conduit or orthotopic ileal bladder substitution. Eur Urol 2012;61:491–497.

77 Novosel EC, Kleinians C, Kluger PJ. Vas- cularization is the key challenge in tissue engi- neering. Adv Drug Deliv Rev 2011;63:300–311.

78 Schepe JR, Amelink A, Wolfenbuttel KP et al. Influence of sildenafil on blood oxygen saturation of the obstructed bladder. BMC Urol 2014;14:44.

79 Arazzi B, Puranik AS, Gauvin R et al. Biomate- rial applications of engineered tissue. Regen Med 2011;6:757–765.
and future directions. Biotechnol Adv 2016; 34:112–121.
86 Cheng G, Liao S, Kit Wong H et al. Engineered blood vessel networks connect to host vasculature via wrapping-and-tapping anastomosis. Blood 2011;118:4740–4749.
87 Sahara M, Sata M, Morita T et al. A phosphodiesterase-5 inhibitor vardenafil enhances angiogenesis through a protein kinase G-dependent hypoxia-inducible factor-1/vascular endothelial growth factor pathway. Arterioscler Thromb Vasc Biol 2010;30:1315–1324.
88 Anderson JM, Rodriguez A, Chang DT. Foreign body reaction to biomaterials. Semin Immunol 2008;20:86–100.
89 Porras AM, Hutson HN, Berger AJ et al. Engineering approaches to study fibrosis in 3-D in vitro systems. Curr Opin Biotechnol 2016;40:24–30.
90 Holmdahl L, Risberg B, Beck DE et al. Adhesions: Pathogenesis and prevention—panel discussion and summary. Eur J Surg Suppl 1997;577:56–62.
91 Boccafoschi F, Mosca C, Cannas M. Cardiovascular biomaterials: When the inflammatory response helps to efficiently restore tissue functionality? J Tissue Eng Regen Med 2014;8:253–267.
92 Meng XM, Nikolic-Paterson DJ, Lan HY. TGF-β: The master regulator of fibrosis. Nat Rev Nephrol 2016;12:325–338.
93 Hawinkels LJ, Ten Dijke P. Exploring anti-TGF-β therapies in cancer and fibrosis. Growth Factors 2011;29:140–152.
94 Opitz CF, Ewert R, Kirch W et al. Inhibition of endothelin receptors in the treatment of pulmonary arterial hypertension: Does selectivity matter? Eur Heart J 2008;29:1936–1948.
95 Raghu G, Brown KK, Bradford WZ et al. Idiopathic Pulmonary Fibrosis Study Group. A placebo-controlled trial of interferon gamma-1b in patients with idiopathic pulmonary fibrosis. N Engl J Med 2004;350:125–133.
96 Miossec P, Kolls JK. Targeting IL-17 and TH17 cells in chronic inflammation. Nat Rev Drug Discov 2012;11:763–776.
97 Badyak S. Host Response to Biomaterials: The Impact of Host Response on Biomaterial Selection. Elsevier 2015.
98 Anderson JM, Rodriguez A, Chang DT. Foreign body reaction to biomaterials. Semin Immunol 2008;20:86–100.
99 Porras AM, Hutson HN, Berger AJ et al. Engineering approaches to study fibrosis in 3-D in vitro systems. Curr Opin Biotechnol 2016;40:24–30.
100 Holmdahl L, Risberg B, Beck DE et al. Adhesions: Pathogenesis and prevention—panel discussion and summary. Eur J Surg Suppl 1997;577:56–62.
101 Boccafoschi F, Mosca C, Cannas M. Cardiovascular biomaterials: When the inflammatory response helps to efficiently restore tissue functionality? J Tissue Eng Regen Med 2014;8:253–267.
102 Meng XM, Nikolic-Paterson DJ, Lan HY. TGF-β: The master regulator of fibrosis. Nat Rev Nephrol 2016;12:325–338.
103 Hawinkels LJ, Ten Dijke P. Exploring anti-TGF-β therapies in cancer and fibrosis. Growth Factors 2011;29:140–152.
104 Opitz CF, Ewert R, Kirch W et al. Inhibition of endothelin receptors in the treatment of pulmonary arterial hypertension: Does selectivity matter? Eur Heart J 2008;29:1936–1948.
105 Guan M, Xu Y, Wang W et al. Differentiation into neurons of rat bone marrow-derived mesenchymal stem cells. Eur Cytokine Netw 2014;25:58–63.
106 Zheng YH, Xiong W, Su K et al. Multilineage differentiation of human bone marrow mesenchymal stem cells in vitro and in vivo. Exp Ther Med 2013;5:1558–1578.
107 Moe AA, Suryana M, Marcy G et al. Microarray with micro- and nanotopographies enables identification of the optimal topography for directing the differentiation of primary murine neural progenitor cells. Small 2012;8:3050–3061.
108 Godier AF, Marolt D, Gerecht S et al. Engineered microenvironments for human stem cells. Birth Defects Res C Embryo Today 2008;84:335–347.
109 Wanjare M, Huang NF. Regulation of the microenvironment for cardiac tissue engineering. Regen Med 2017;12:187–201.
110 Huang NF, Li S. Regulation of the matrix microenvironment for stem cell engineering and regenerative medicine. Ann Biomed Eng 2011;39:1201–1214.
111 Nakayama KH, Hou L, Huang NF. Role of extracellular matrix signaling cues in modulating cell fate commitment for cardiovascular tissue engineering. Adv Healthc Mater 2014;3: 628–641.
112 Vishwakarma A, Bhise NS, Evangelista MB et al. Engineering immunomodulatory biomaterials to tune the inflammatory response. Trends Biotechnol 2016;34:470–82.